You are here: Industry Insights > Astellas

News List

Pfizer, Astellas rocket toward broader Xtandi use with FDA 'priority' tag fiercepharma
August 25, 2019
Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to a new move from the FDA, they might not have to wait that long.
Astellas Initiates Phase 3 Clinical Trials for Fezolinetant biospectrumasia
August 08, 2019
Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist. The first trials of the BRIGHT SKY™ clinical development program will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing VMS frequency and severity.
Astellas Appoints SVP and Head Clinical and Research QA contractpharma
August 07, 2019
Fryrear, brings more than 30 years of pharmaceutical industry experience, holding senior leadership roles at AbbVie and Eli Lilly.
Astellas submits biologics license application for Urothelial Cancer drug biospectrumasia
July 28, 2019
Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology
Astellas licences Frequency Therapeutics’ hearing loss drug pharmaceutical-technology
July 19, 2019
Astellas Pharma has signed an exclusive licensing agreement to develop and commercialise Frequency Therapeutics’ drug candidate FX-322 for sensorineural hearing loss.
Astellas, Frequency Therapeutics Enter Alliance for Hearing Loss Treatment contractpharma
July 18, 2019
Aims to develop and commercialize Frequency’s candidate, FX-322, for the treatment of sensorineural hearing loss.
Astellas, Seattle Genetics Announce BLA Submission for Enfortumab Vedotin americanpharmaceuticalreview
July 17, 2019
Astellas Pharma and Seattle Genetics announced submission of a Biologics License Application for accelerated approval to the U.S. Food and Drug Administration for the investigational agent enfortumab vedotin for the ...
Astellas Appoints National Oncology Sales VP contractpharma
July 11, 2019
Chelsea Glinski is recognized by the Healthcare Businesswomen's Association (HBA) as a 2019 Luminary.
Otsuka Chemical Enters API Business contractpharma
June 19, 2019
Acquires cefixime business from Astellas.
Amgen and Astellas Pharma US agree to settlement costs for kickback charges europeanpharmaceuticalreview
May 05, 2019
Amgen and Astellas Pharma US have agreed to pay a total of $124.75 million to settle allegations that they paid kickbacks to Medicare copays for their own medications.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page